Evidence map›Paper›PMID 41929510›Full record

ArticleFrontiers in immunology2026

CX3CR1 identifies a potent effector CD8

Jiajin Ma, Yue Wu, Rongzhang Chen, Nuo Wang, Yirui Liu, Lujun Chen, Shaoxian Wu, Xiao Zheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiajin MaDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Yue WuDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Rongzhang ChenDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Nuo WangDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Yirui LiuDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Lujun ChenDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Shaoxian WuDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Xiao ZhengDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The therapeutic landscape for deficient mismatch repair (dMMR) colorectal cancer (CRC) has been fundamentally transformed by the introduction of immune checkpoint inhibitors (ICIs). Yet, a significant fraction of patients exhibits primary or acquired resistance, underscoring a critical unmet need to decode the heterogeneity of tumor-infiltrating CD8 Methods: By leveraging a multi-dimensional approach that combined single-cell RNA sequencing (scRNA-seq), multiplex immunohistochemistry (mIHC), extensive clinical data mining, and Results: We uncovered a unique CX3CR1 Conclusion: This study characterizes CX3CR1

Indexed as

CD8-Positive T-LymphocytesColorectal NeoplasmsCX3C Chemokine Receptor 1Immune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingProgrammed Cell Death 1 ReceptorT-Lymphocyte SubsetsAnimalsFemaleHumansMiceT-Cell ExhaustionCX3C Chemokine Receptor 1CX3CR1 protein, humanImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptorcolorectal cancerCX3CR1+CD8+T cellsimmunotherapymulti-color immunohistochemical stainingprognosis

Identifiers

PMID41929510
PMCPMC13039036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.